World Antimalarial Resistance Network I

Clinical efficacy of antimalarial drugs

Ric Price, Grant Dorsey, Elizabeth Ashley, K Barnes, J Kevin Baird, Umberto D'Alessandro, Philippe Guerin, M Laufer, I Naidoo, François Nosten, Piero Olliaro, C Plowe, P RINGWALD, C Sibley, Kasia Stepniewska, N WHITE

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    The proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch a concerted global surveillance effort to monitor antimalarial drug efficacy. The diversity of clinical study designs and analytical methods undermines the current ability to achieve this. The proposed World Antimalarial Resistance Network (WARN) aims to establish a comprehensive clinical database from which standardised estimates of antimalarial efficacy can be derived and monitored over time from diverse geographical and endemic regions. The emphasis of this initiative is on five key variables which define the therapeutic response. Ensuring that these data are collected at the individual patient level in a consistent format will facilitate better data management and analytical practices, and ensure that clinical data can be readily collated and made amenable for pooled analyses. Such an approach, if widely adopted will permit accurate and timely recognition of trends in drug efficacy. This will guide not only appropriate interventions to deal with established multidrug resistant strains of malaria, but also facilitate prompt action when new strains of drug resistant plasmodia first emerge. A comprehensive global database incorporating the key determinants of the clinical response with in vitro, molecular and pharmacokinetic parameters will bring together relevant data on host, drug and parasite factors that are fundamental contributors to treatment efficacy. This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed. � 2007 Price et al; licensee BioMed Central Ltd.
    Original languageEnglish
    Pages (from-to)1-9
    Number of pages9
    JournalMalaria Journal
    Volume6
    Issue number119
    Publication statusPublished - 2007

    Fingerprint

    Antimalarials
    Pharmaceutical Preparations
    Databases
    Plasmodium
    Practice Management
    Malaria
    Parasites
    Pharmacokinetics

    Cite this

    Price, R., Dorsey, G., Ashley, E., Barnes, K., Baird, J. K., D'Alessandro, U., ... WHITE, N. (2007). World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs. Malaria Journal, 6(119), 1-9.
    Price, Ric ; Dorsey, Grant ; Ashley, Elizabeth ; Barnes, K ; Baird, J Kevin ; D'Alessandro, Umberto ; Guerin, Philippe ; Laufer, M ; Naidoo, I ; Nosten, François ; Olliaro, Piero ; Plowe, C ; RINGWALD, P ; Sibley, C ; Stepniewska, Kasia ; WHITE, N. / World Antimalarial Resistance Network I : Clinical efficacy of antimalarial drugs. In: Malaria Journal. 2007 ; Vol. 6, No. 119. pp. 1-9.
    @article{19f15acb1a2a44099c6375104f6282bd,
    title = "World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs",
    abstract = "The proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch a concerted global surveillance effort to monitor antimalarial drug efficacy. The diversity of clinical study designs and analytical methods undermines the current ability to achieve this. The proposed World Antimalarial Resistance Network (WARN) aims to establish a comprehensive clinical database from which standardised estimates of antimalarial efficacy can be derived and monitored over time from diverse geographical and endemic regions. The emphasis of this initiative is on five key variables which define the therapeutic response. Ensuring that these data are collected at the individual patient level in a consistent format will facilitate better data management and analytical practices, and ensure that clinical data can be readily collated and made amenable for pooled analyses. Such an approach, if widely adopted will permit accurate and timely recognition of trends in drug efficacy. This will guide not only appropriate interventions to deal with established multidrug resistant strains of malaria, but also facilitate prompt action when new strains of drug resistant plasmodia first emerge. A comprehensive global database incorporating the key determinants of the clinical response with in vitro, molecular and pharmacokinetic parameters will bring together relevant data on host, drug and parasite factors that are fundamental contributors to treatment efficacy. This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed. � 2007 Price et al; licensee BioMed Central Ltd.",
    keywords = "antimalarial agent, clinical trial, drug efficacy, drug monitoring, drug use, follow up, host, human, in vitro study, malaria, multidrug resistance, Plasmodium, review, survival, treatment response, article, clinical trial (topic), data base, drug combination, health, Internet, treatment outcome, Antimalarials, Clinical Trials as Topic, Databases as Topic, Drug Resistance, Multiple, Drug Therapy, Combination, Humans, Malaria, Survival Analysis, Treatment Outcome, World Health",
    author = "Ric Price and Grant Dorsey and Elizabeth Ashley and K Barnes and Baird, {J Kevin} and Umberto D'Alessandro and Philippe Guerin and M Laufer and I Naidoo and Fran{\~A}§ois Nosten and Piero Olliaro and C Plowe and P RINGWALD and C Sibley and Kasia Stepniewska and N WHITE",
    year = "2007",
    language = "English",
    volume = "6",
    pages = "1--9",
    journal = "Malaria Journal",
    issn = "1475-2875",
    publisher = "BioMed Central",
    number = "119",

    }

    Price, R, Dorsey, G, Ashley, E, Barnes, K, Baird, JK, D'Alessandro, U, Guerin, P, Laufer, M, Naidoo, I, Nosten, F, Olliaro, P, Plowe, C, RINGWALD, P, Sibley, C, Stepniewska, K & WHITE, N 2007, 'World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs', Malaria Journal, vol. 6, no. 119, pp. 1-9.

    World Antimalarial Resistance Network I : Clinical efficacy of antimalarial drugs. / Price, Ric; Dorsey, Grant; Ashley, Elizabeth; Barnes, K; Baird, J Kevin; D'Alessandro, Umberto; Guerin, Philippe; Laufer, M; Naidoo, I; Nosten, François; Olliaro, Piero; Plowe, C; RINGWALD, P; Sibley, C; Stepniewska, Kasia; WHITE, N.

    In: Malaria Journal, Vol. 6, No. 119, 2007, p. 1-9.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - World Antimalarial Resistance Network I

    T2 - Clinical efficacy of antimalarial drugs

    AU - Price, Ric

    AU - Dorsey, Grant

    AU - Ashley, Elizabeth

    AU - Barnes, K

    AU - Baird, J Kevin

    AU - D'Alessandro, Umberto

    AU - Guerin, Philippe

    AU - Laufer, M

    AU - Naidoo, I

    AU - Nosten, François

    AU - Olliaro, Piero

    AU - Plowe, C

    AU - RINGWALD, P

    AU - Sibley, C

    AU - Stepniewska, Kasia

    AU - WHITE, N

    PY - 2007

    Y1 - 2007

    N2 - The proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch a concerted global surveillance effort to monitor antimalarial drug efficacy. The diversity of clinical study designs and analytical methods undermines the current ability to achieve this. The proposed World Antimalarial Resistance Network (WARN) aims to establish a comprehensive clinical database from which standardised estimates of antimalarial efficacy can be derived and monitored over time from diverse geographical and endemic regions. The emphasis of this initiative is on five key variables which define the therapeutic response. Ensuring that these data are collected at the individual patient level in a consistent format will facilitate better data management and analytical practices, and ensure that clinical data can be readily collated and made amenable for pooled analyses. Such an approach, if widely adopted will permit accurate and timely recognition of trends in drug efficacy. This will guide not only appropriate interventions to deal with established multidrug resistant strains of malaria, but also facilitate prompt action when new strains of drug resistant plasmodia first emerge. A comprehensive global database incorporating the key determinants of the clinical response with in vitro, molecular and pharmacokinetic parameters will bring together relevant data on host, drug and parasite factors that are fundamental contributors to treatment efficacy. This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed. � 2007 Price et al; licensee BioMed Central Ltd.

    AB - The proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch a concerted global surveillance effort to monitor antimalarial drug efficacy. The diversity of clinical study designs and analytical methods undermines the current ability to achieve this. The proposed World Antimalarial Resistance Network (WARN) aims to establish a comprehensive clinical database from which standardised estimates of antimalarial efficacy can be derived and monitored over time from diverse geographical and endemic regions. The emphasis of this initiative is on five key variables which define the therapeutic response. Ensuring that these data are collected at the individual patient level in a consistent format will facilitate better data management and analytical practices, and ensure that clinical data can be readily collated and made amenable for pooled analyses. Such an approach, if widely adopted will permit accurate and timely recognition of trends in drug efficacy. This will guide not only appropriate interventions to deal with established multidrug resistant strains of malaria, but also facilitate prompt action when new strains of drug resistant plasmodia first emerge. A comprehensive global database incorporating the key determinants of the clinical response with in vitro, molecular and pharmacokinetic parameters will bring together relevant data on host, drug and parasite factors that are fundamental contributors to treatment efficacy. This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed. � 2007 Price et al; licensee BioMed Central Ltd.

    KW - antimalarial agent

    KW - clinical trial

    KW - drug efficacy

    KW - drug monitoring

    KW - drug use

    KW - follow up

    KW - host

    KW - human

    KW - in vitro study

    KW - malaria

    KW - multidrug resistance

    KW - Plasmodium

    KW - review

    KW - survival

    KW - treatment response

    KW - article

    KW - clinical trial (topic)

    KW - data base

    KW - drug combination

    KW - health

    KW - Internet

    KW - treatment outcome

    KW - Antimalarials

    KW - Clinical Trials as Topic

    KW - Databases as Topic

    KW - Drug Resistance, Multiple

    KW - Drug Therapy, Combination

    KW - Humans

    KW - Malaria

    KW - Survival Analysis

    KW - Treatment Outcome

    KW - World Health

    M3 - Article

    VL - 6

    SP - 1

    EP - 9

    JO - Malaria Journal

    JF - Malaria Journal

    SN - 1475-2875

    IS - 119

    ER -

    Price R, Dorsey G, Ashley E, Barnes K, Baird JK, D'Alessandro U et al. World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs. Malaria Journal. 2007;6(119):1-9.